Table 2.
Association between FAS and FASLG genotypes and SCCOP recurrence in patients with SCCOP (N = 1008)
| Genotype | No. of recurrences/no. of patients | 5-year recurrence rate | Log-rank P value | aHR*, 95% CI |
|---|---|---|---|---|
| FAS1377G>A | ||||
|
| ||||
| GG (ref.)a | 152/872 | 0.19 | 0.323 | 1.0 |
| GA | 28/128 | 0.22 | 1.1 (0.4–1.4) | |
| AA | 1/8 | 0.18 | 0.9 (0.3–1.2) | |
| Ptrend | 0.662 | |||
|
| ||||
| GG (ref.) | 152/872 | 0.19 | 0.211 | 1.0 |
| GA+AA | 29/136 | 0.22 | 1.1 (0.8–2.0) | |
|
| ||||
| FAS670A>G | ||||
|
| ||||
| AA (ref.)a | 36/449 | 0.10 | 0.0021 | 1.0 |
| AG | 106/430 | 0.28 | 2.7 (2.1–9.2) | |
| GG | 39/129 | 0.21 | 4.2 (0.8–10.3) | |
| Ptrend | 0.024 | |||
|
| ||||
| AA (ref.) | 36/449 | 0.10 | < 0.0001 | 1.0 |
| AG+GG | 145/559 | 0.28 | 3.2 (2.2–4.6) | |
|
| ||||
| FASLG844C>T | ||||
|
| ||||
| CC (ref.)a | 42/491 | 0.11 | 0.0011 | 1.0 |
| CT | 111/420 | 0.27 | 3.3 (1.7–9.8) | |
| TT | 28/97 | 0.29 | 3.8 (0.7–11.4) | |
| Ptrend | 0.132 | |||
|
| ||||
| CC (ref.) | 42/491 | 0.11 | < 0.0001 | 1.0 |
| CT+TT | 139/517 | 0.28 | 3.1 (2.2–4.4) | |
|
| ||||
| FASLG124A>G | ||||
|
| ||||
| AA (ref.)a | 119/715 | 0.19 | 0.226 | 1.0 |
| AG | 56/265 | 0.23 | 1.5 (0.9–2.4) | |
| GG | 6/28 | 0.20 | 1.1 (0.4–2.8) | |
| Ptrend | 0.743 | |||
|
| ||||
| AA (ref.) | 119/715 | 0.19 | 0.121 | 1.0 |
| AG+GG | 62/293 | 0.22 | 1.4 (0.9–2.0) | |
HR, hazard ratio.
*
Adjusted for age, sex, ethnicity, smoking status, alcohol use status, stage, comorbidity, and treatment.
a
The observed genotype frequencies were in agreement with the Hardy-Weinberg equilibrium (p2 + 2pq + q2 = 1). (HWE by χ2 tests: P = 0.175 for FAS1377, P = 0.104 for FAS670, P = 0.603 for FASLG844, and P = 0.565 for FASLG124, respectively).